Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response. Long-term follow-up data offer valuable ...

Kezar Life Sciences said on Thursday it would terminate its mid-stage trial studying its experimental drug in patients with active lupus nephritis and focus on the development of the drug in ...

known as lupus nephritis (LN). Credit: SciePro via Shutterstock. Clinical stage biopharma company Kezar Life Sciences is discontinuing its LN clinical programme following the death of four patients.

Aurinia Pharma and partner Otsuka have secured approval in the EU for Lupkynis, billed as the first oral treatment for active nephritis in patients with the autoimmune disease systemic lupus ...

Systemic lupus is the most common form of lupus—it’s what most people mean when they refer to “lupus.” Systemic lupus can be mild or severe. Cutaneous lupus erythematosus This form of lupus is limited ...

From there, assuming housing costs could not exceed 30% of gross income, GOBankingRates found the minimum salary needed to comfortably afford a home in each state. Ranked in order of states where ...

Walk to End Lupus Now ™ events provide all people affected by Lupus and their families the opportunity to come together for one unified purpose — to end Lupus. Join the Lupus Foundation of America and ...

Proposition 32 asks California voters to raise the state's minimum wage to $18 over the next two years, making it the highest minimum wage in the nation. For employers with 26 or more employees ...

That's because of required minimum distributions (RMD), which are mandatory withdrawals that must be made from retirement accounts starting at age 73. In part thanks to market performance swelling ...

What kind of doctor treats lupus? It's a common question for those who may have or have been diagnosed with systemic lupus erythematosus (SLE) or another form of lupus. Since most people with lupus ...

CYC and rituximab should be considered in organ-threatening and refractory disease, respectively. For active lupus nephritis, GC, mycophenolate or low-dose intravenous CYC are recommended as anchor ...